Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in type 2 diabetes mellitus

被引：0
|
作者：
Kelley, DE
Mckolanis, TM
Kelley, CA
机构：
来源：
DIABETES | 2002年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
142
引用
收藏
页码：A35 / A35
页数：1
相关论文
共 50 条
  • [31] Relationship of visceral and subcutaneous adiposity with renal function in people with type 2 diabetes mellitus
    Kim, Sung Rae
    Yoo, Ji Han
    Song, Ho Cheol
    Lee, Seong Su
    Yoo, Soon Jib
    Kim, Young-Du
    Lim, Yeon Soo
    Kim, Hyung Wook
    Yang, Chul Woo
    Kim, Yong-Soo
    Choi, Euy Jin
    Kim, Yong Kyun
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (11) : 3550 - 3555
  • [32] Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes
    Stage, Tore Bjerregaard
    Christensen, Mette-Marie Hougaard
    Jorgensen, Niklas Rye
    Beck-Nielsen, Henning
    Brosen, Kim
    Gram, Jeppe
    Frost, Morten
    BONE, 2018, 112 : 35 - 41
  • [33] Complementary mode of action of rosiglitazone and metformin in a single tablet for the treatment of diabetes mellitus type 2
    Petersen, KU
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2004, 54 (01): : 20 - 30
  • [34] Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus
    Banerji, M
    Lebovitz, H
    Dugbartey, M
    DIABETES, 2001, 50 : A90 - A90
  • [35] The impact of therapy with rosiglitazone (RSG) versus metformin (MET) on liver associated enzymes (LAEs) in patients with type 2 diabetes mellitus
    Mann, K
    Mulhall, B
    Maydonovitch, C
    Stocker, D
    Vigersky, R
    Holtzmuller, K
    GASTROENTEROLOGY, 2004, 126 (04) : A757 - A757
  • [36] Effects of Rosiglitazone vs Metformin on Circulating Osteoclast and Osteogenic Precursor Cells in Postmenopausal Women with Type 2 Diabetes Mellitus
    Rubin, M. R.
    Manavalan, J. S.
    Agarwal, S.
    McMahon, D. J.
    Nino, A.
    Fitzpatrick, L. A.
    Bilezikian, J. P.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (10): : E1933 - E1942
  • [37] Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes
    Iozzo, P
    Hallsten, K
    Oikonen, V
    Virtanen, KA
    Parkkola, R
    Kemppainen, J
    Solin, O
    Lonnqvist, F
    Ferrannini, E
    Knuuti, J
    Nuutila, P
    DIABETES CARE, 2003, 26 (07) : 2069 - 2074
  • [38] Metformin for Type 2 diabetes mellitus
    MacDonald, Blair J.
    Turgeon, Ricky D.
    McCormack, James
    ACADEMIC EMERGENCY MEDICINE, 2024, 31 (08) : 832 - 834
  • [39] Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome
    Derosa, G
    Gaddi, AV
    Piccinni, MN
    Ciccarelli, L
    Salvadeo, S
    Peros, E
    Ghelfi, M
    Ferrari, I
    Cicero, AFG
    PHARMACOTHERAPY, 2005, 25 (05): : 637 - 645
  • [40] Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis
    Du, Qiang
    Wu, Bo
    Wang, Yan-Jun
    Yang, Sheng
    Zhao, Yue-Yang
    Liang, Yuan-yuan
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (11) : 1487 - 1494
12345